A New York jury has ordered Merck to pay $8 million in damages in a defective drug lawsuit alleging that their product, Fosamax, caused a 72-year-old woman to develop osteonecrosis of the jaw. It is the second Fosamax lawsuit to reach a verdict, and the first to award damages to the plaintiff. Merck had won the only other Fosamax claim to reach a verdict back in May.
The jury found Fosamax to be defectively designed and unreasonably dangerous. They awarded the plaintiff $3 million more than she requested. Merck plans to ask the judge to throw out the verdict, claiming the jury’s verdict and damage award did not align with the evidence. If the verdict is not set aside, Merck plans to file an appeal.
Currently, there are approximately 978 defective drug claims pending against Merck for injuries associated with taking Fosamax. Some of these are class action cases, containing multiple plaintiffs. There have been numerous reports of patients developing osteonecrosis of the jaw from taking the popular osteoporosis drug.
If you have suffered an injury from taking Fosamax, you may be entitled to receive compensation for your damages. An experienced defective drug attorney can help protect your rights in court.
If you have a Fosamax claim, please contact the experienced pharmaceutical injury attorneys at Schlichter, Bogard & Denton today to schedule your free initial consultation. Schlicthter, Bogard & Denton serves clients nationwide.